Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 12837 results found since Jan 2013.
Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)
CONCLUSIONS: Patients in the trastuzumab+pertuzumab group had a higher pCR rate than those in the trastuzumab group, and the toxic side effects were tolerable.PMID:36535009 | DOI:10.1097/CM9.0000000000002197
Source: Chinese Medical Journal - December 19, 2022 Category: General Medicine Authors: Yuanjia Cheng Hongyu Xiang Ling Xin Xuening Duan Yinhua Liu Chinese Society of Breast Surgery (CSBrS), Chinese Society of Surgery of Chinese Medical Association Source Type: research
Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials
Abstract
The timing of surgery and antineoplastic therapies in patients with resectable non-metastatic pancreatic cancer is still a controversial matter of debate, with special regard to neoadjuvant approaches. Following the criteria of the PRISMA statement, a literature search was conducted looking for RCTs focusing on adjuvant and neoadjuvant therapies in resectable pancreatic cancer. The quality of the available evidence was assessed using the Cochrane Collaboration’s tool for assessing risk of bias. Data extraction was carried out by two independent investigators. The search led to the identification of 283...
Source: Medical Oncology - February 17, 2016 Category: Cancer & Oncology Source Type: research
Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer.
CONCLUSIONS: Early identification and prompt treatment of subclinical cardiotoxicity may improve cardiologic prognosis of these patients and may allow oncologists to avoid withdrawal of chemotherapy. That is why it becomes always more important the creation of multidisciplinary teams where cardiologists and oncologists work together to ensure optimal care to oncologic patients treated with cardiotoxic agents.
PMID: 29687878 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - April 26, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Pre-therapeutic molecular biomarkers of pathological response to neoadjuvant chemotherapy in gastric and esophago-gastric junction adenocarcinoma: A systematic review and meta-analysis
CONCLUSION: Previous studies describe a large number of candidate biomarkers. Our meta-analysis indicated pre-therapeutic serum concentration of CEA >5 ng/mL as a potential and easy-accessible biomarker available for use before initiation of treatment. However, it could be only an additional tool for complex qualification for neoadjuvant therapy.PMID:36944288 | DOI:10.1016/j.advms.2023.02.005
Source: Advances in Medical Sciences - March 21, 2023 Category: Biomedical Science Authors: Kamil Nurczyk Norbert Nowak Rebecca Carlson Tomasz Skoczylas Grzegorz Wallner Source Type: research
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
ConclusionWe see the use of BRAF Inhibitors to reduce tumor size with consecutive surgical treatment as a reasonable option for therapy. However, we are aware that at present the data are based only on case reports with the longest follow-up of just 38 months. We encourage further clinical trials in the use of BRAF Inhibitors for selecting ameloblastoma patients in a multi-center setting.
Source: Medical Oncology - April 28, 2023 Category: Cancer & Oncology Source Type: research
Surgical concepts in esophageal cancer
SummaryDespite neoadjuvant treatment being available for esophageal cancer, surgery remains the cornerstone of treatment. The aim of this article is to give a clear and simple overview of current issues in the available surgical strategies relating to locally limited and advanced disease, including the following: clinical staging, preoperative general condition and comorbidities, surgical strategy, surgical approaches, postoperative complications and the role of surgery in advanced disease. Based on a literature search and our personal professional experience to date, enhanced surgical treatment protocols for the treatment...
Source: Memo - Magazine of European Medical Oncology - January 29, 2019 Category: Cancer & Oncology Source Type: research
Risk factors analysis for surgical site infection following elective colorectal resection: a retrospective regression analysis.
CONCLUSIONS: Age, surgical duration, and pre-operative oral antibiotic use were associated with the incidence of SSI. However, pre-operative oral antibiotic use was the only controllable factor. From the results of our study, pre-operative oral antibiotic use is recommended before elective colorectal surgery and a 1-day course is enough to provide the protective effect.
PMID: 31996547 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - January 27, 2020 Category: General Medicine Authors: Lei PR, Liao JW, Ruan Y, Yang XF, Hu KP, Liu JP, Chen TF Tags: Chin Med J (Engl) Source Type: research
Effectiveness of a Rectal Cancer Education Video on Patient Expectations
CONCLUSIONS: Patients have varying expectations of problematic control of bowel, urinary, and sexual function following rectal cancer treatments. A pre-treatment education video resulted in a trend towards changed expectations for functional outcomes in most patients. Further educational modalities for patients may provide more uniform expectations of function and increase patient satisfaction after rectal cancer treatments.PMID:35396809 | DOI:10.1111/codi.16143
Source: Cancer Control - April 9, 2022 Category: Cancer & Oncology Authors: Lucas D Streith Silas J Y Yip Carl J Brown Ahmer A Karimuddin Manoj J Raval P Terry Phang Amandeep Ghuman Source Type: research
A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes
Clin Cancer Res. 2021 Jun 9:clincanres.1133.2021. doi: 10.1158/1078-0432.CCR-21-1133. Online ahead of print.ABSTRACTWhile COVID-19 vaccine distribution has addressed vulnerabilities related to age and co-morbidities, there is a need to ensure vaccination of cancer patients receiving experimental and routine treatment, where interruption of treatment by infection is likely to result in inferior outcomes. Among cancer patients, those undergoing neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (Adj chemo) for early breast cancer (EBC) are at particularly high risk for inferior outcomes, in part because optimal timing o...
Source: Clinical Cancer Research - June 10, 2021 Category: Cancer & Oncology Authors: David A Potter Alexandra Thomas Hope S Rugo Source Type: research
